Table 2.
Sequencing Metrics of Individual Sequencing Approaches.
| Specimen | Sample number | Mean mutations/ sample | Gene-panel (size) | Mean sequencing reads (×106) | Median unique read depth | Mean on-target rate (%) | Mean mutation coverage |
|---|---|---|---|---|---|---|---|
| Tumor biopsy | 11 | 20.5 | SureSelectTM XT HS (4800 genes and regions) | 51.9 | 171.2 | 92.8 | 24.9 |
| Resection | 1 | 30 | SureSelectTM XT HS (4800 genes and regions) | 95.1 | 267 | 92.6 | 34 |
| Plasma | 14 | 7.6 | AVENIOTM ctDNA Surveillance (17 genes / regions, 180 hotspots) | 77.6 | 2930 | 72.5 | 45 |
| Stool | 12 | 3.9 | AVENIOTM ctDNA Surveillance (17 genes / regions, 180 hotspots) | 73.4 | 229.5 | 54.7 | 23.4 |
Sequencing metrics of all samples derived from specific specimens analyzed with SureSelectTM XT HS Focused Exome or AVENIOTM ctDNA Surveillance approach. The SureSelectTM XT HS Focused Exome approach contains non-synonymous exonic (+-10 bp flanking regions) variants. The specimens sequenced via the AVENIOTM ctDNA Surveillance approach include synonymous and non-synonymous mutations within the exonic (+-20 bp flanking regions) region.